Seqirus Overview
Company Headquarters: Maidenhead, UK
Founded: 2015
Workforce: ~1001-5000
Company Working: Seqirus was established in July 2015, following the Commonwealth Serum Laboratories (CSL)’s acquisition of the Novartis influenza vaccines business, and subsequent integration with bioCSL. Seqirus is one of the world’s largest influenza vaccine companies and is one of the major partners in the prevention and control of influenza globally. The company is a reliable supplier of influenza vaccine for northern and southern hemisphere markets. Each Seqirus facility provides pandemic preparedness to their host countries as well as other countries in their respective regions.
Seqirus utilizes both egg-based and cell-culture based manufacturing technologies as well as a proprietary adjuvant for vaccine production. The company has leading R&D capabilities, a broad and differentiated product portfolio, and commercial operations in more than 20 countries. In Australia and the Asia-Pacific region, Seqirus is a leading provider of in-licensed vaccines and specialty pharmaceuticals.
Strategy
Seqirus’s vision is to protect the world from influenza. The company has built an active global business that serves significant public health needs. It has one of the broadest and most differentiated influenza vaccine portfolios in the industry. The ongoing shift in product mix from standard trivalent influenza vaccines to cell-based quadrivalent and adjuvanted products is a significant driver for the growth of this company.
